SCOPE Shorts

SCOPE PLANNING COMMITTEE MEMBERS REPRESENT RESEARCH AND CLINICAL PRACTICE WITHIN UNIVERSITIES, HOSPITALS, CORPORATIONS, FOUNDATIONS, AND FEDERAL AGENCIES.

The Planning Committee of the Spinal Cord Outcomes Partnership Endeavor (SCOPE) is a group of experienced individuals, representing a variety of constituencies within spinal cord medicine.

SCOPE leaders:

Jane Hsieh, MSc, Co-Chair
Wings for Life
After receiving graduate neurophysiology training at McGill University, Jane has spent more than 30 years in spinal cord injury (SCI) research.  Throughout her career, Jane has been involved with SCI research in academia, industry, non-profit organizations and in my own consulting business. Currently, Jane’s main focus is acting as the Executive Director of the Accelerated Translational Program of Wings for Life. Managing this portfolio requires up to date knowledge of SCI clinical trials from both scientific and operational perspectives. Overseeing two large multi-centre drug trials in chronic SCI and many smaller complex multi-centre trials in acute, chronic, drug, device, and biologic therapeutics has afforded Jane extensive experience in all aspects and types of clinical trials.  

Linda Jones, PT, PhD, Co-Chair
University of Colorado
With more than 20 years of experience, Linda has applied her clinical expertise, serving as a consultant and staff member in a number of pharmaceutical, biotechnology, exoskeleton and healthcare settings. She worked at Geron Corporation from 2006-2011, preparing and managing the first clinical trial in the United States utilizing cells derived from human embryonic stem cells, in a Phase I study in patients with neurologically complete, sub-acute spinal cord injury. Prior to this, she worked with Proneuron Biotechnologies, the sponsor of the first Phase 1 cell-based study (autologous macrophage injection) in spinal cord injury, and subsequently managed the Phase II trial. Linda also worked at Denver Health Medical Center for 12 years, with a focus on physical therapy interventions in the intensive care unit. Linda has also participated in publications on updates to and challenging cases based on the International Standards for the Neurological Classification of Spinal Cord Injury.

SCOPE Members:

Linda Bambrick, PhD
National Institute of Neurological Disorders and Stroke (NINDS)

Andrew R. Blight, PhD
Acorda Therapeutics, Inc.

Philippe Chambon MD, PhD
EG427 

Mikael Contrastin
EG427 

Gregoire Courtine, PhD
Onward

Brian Culley
Lineage

Armin Curt, MD, FRCPC
Spinal Cord Injury Center | University of Zurich

Jessica D’Amico, PhD
Onward

Marc DePaul, PhD
NervGen Pharma

Adele Doperalski, PhD
NINDS

Eberhardt Elizabeth
NervGen Pharma

Vieri Faili, PhD
Wings for Life

Adam Ferguson, PhD
University of California, San Francisco

Edelle Field-Fote, PT, PhD, FAPTA
Shepherd Center, Atlanta

Dan Graves, PhD
Thomas Jefferson Hospital

James Guest, MD, PhD, FACS
The Miami Project to Cure Paralysis | University of Miami Miller School of Medicine

Cornelia Haag-Molkenteller, MD, PhD
CMO, EG47

James Hamer, BA
DP Clinical

Ioana Hone
Lineage

Catherine Jutzeler, Dr
ETH Zürich

Genki Kaneko
Mitsubishi Tanabe Pharma

Steven Kirshblum, MD
Kessler Institute for Rehabilitation

Naomi Kleitman, PhD
Craig H. Neilsen Foundation

John Kramer, PhD
ICORD

Audrey Kusiak, PhD
Department of Veterans Affairs Office of Research and Development

Daniel P. Lammerstse, MD
Craig Hospital

Dave Marver
Onward

Verena May, PhD
Wings for Life

Dan Mikol, MD, PhD
NervGen Pharma

Mary Jane Mulcahey, PhD, OTR/L
Jefferson School of Health Professions | Thomas Jefferson University

Kent New, MD, PhD
Ascension St. Vincent’s Neurosurgery

Nancy Nicholas
SCI Community Liaison

Kim Pfleeger
AbbVie

Devinder Poonian
DP Clinical

Erika Ross
Onward

John Steeves, PhD
University of British Columbia and Vancouver Coastal Health | Vancouver General Hospital

Keith Tansey, MD, PhD
University of Mississippi Medical Center | Spinal Cord Injury Clinic at the Jackson VA Medical Center

Tracey Wheeler, PhD
Craig Neilsen Foundation

Konstantin Zubovskiy         
Mitsubishi Tanabe Pharma